Hemohim - Apa Kata Saintis?
Perhatikan cara penulis membuat rumusan tentang kajian mereka.
"These results indicate that HemoHIM may have potential as a glucose-lowering and immunomodulatory agent by enhancing the immune function of pancreatic β-cells in STZ-induced diabetic mice."
1) Mereka guna perkataan 'potential'. Maksudnya, ada bukti bahawa Hemohim MUNGKIN berkesan. Tapi belum ada bukti yang cukup kuat bahawa ia berkesan. Potensi itupun didahulukan dengan 'may have'. Mungkin ada. bukannya dah terbukti ada.
2) Potensi Hemohim diuji ke atas tikus. Kajian ini tidak menguji keberkesanannya ke atas MANUSIA.
3) Potensi keberkesanan Hemohim ini diuji ke atas tikus yang dikenakan (induced) diabetes (maksudnya, bukan diabetes yang berlaku secara biasa). Maksudnya, tikus makmal tu asalnya sihat, tapi diberi bahan kimia untuk menjadikan mereka mendapat diabetes.
Kajian terbaharu yang saya jumpa pun masih menggunakan tikus makmal.
Synergistic Anti-cancer Activity of MH-30 in a Murine Melanoma Model Treated with Cisplatin and its Alleviated Effects against Cisplatin-induced Toxicity in Mice
DOI: 10.21873/invivo.11979
Apa maksudnya?
Artikel ini sahaja TIDAK boleh digunakan untuk membuat claim bahawa Hemohim berkesan ke atas manusia. Kalau ada ejen Atomy ytang membuat claim sedemikian, maka tanyalah dia tentang artikel-artikel yang seperti ini.
====
HemoHIM (a new herbal preparation of three edible herbs: Angelica gigas Nakai, Cnidium officinale Makino, and Paeonia japonica Miyabe) was developed to protect immune, hematopoietic, and self-renewal tissues against radiation. This study determined whether or not HemoHIM could alter hyperglycemia and the immune response in diabetic mice. Both nondiabetic and diabetic mice were orally administered HemoHIM (100 mg/kg) once a day for 4 weeks. Diabetes was induced by single injection of streptozotocin (STZ, 200 mg/kg, i.p.). In diabetic mice, HemoHIM effectively improved hyperglycemia and glucose tolerance compared to the diabetic control group as well as elevated plasma insulin levels with preservation of insulin staining in pancreatic β-cells. HemoHIM treatment restored thymus weight, white blood cells, lymphocyte numbers, and splenic lymphocyte populations (CD4+ T and CD8+ T), which were reduced in diabetic mice, as well as IFN-γ production in response to Con A stimulation. These results indicate that HemoHIM may have potential as a glucose-lowering and immunomodulatory agent by enhancing the immune function of pancreatic β-cells in STZ-induced diabetic mice.
Comments